Updated:
US BioTek Laboratories
US BioTek Laboratories was established in 2000 as a specialized clinical reference laboratory, building its early reputation on advanced diagnostic...
US BioTek Laboratories
US BioTek Laboratories was established in 2000 as a specialized clinical reference laboratory, building its early reputation on advanced diagnostic testing for environmental allergens and food sensitivities. The firm operates a high-complexity CLIA-certified facility in Shoreline, Washington, processing hundreds of thousands of patient specimens annually for a national client base of functional medicine practitioners and primary care physicians. The laboratory's core analytical platforms span three distinct testing modalities: multiplex ELISA-based immunology panels, LC-MS/MS toxicology, and real-time PCR molecular assays. Confirmed testing categories include comprehensive respiratory allergen profiles, IgG-mediated food sensitivity panels, and quantitative urinary mycotoxin detection, per CLIA validation records. The firm serves all 50 US states, accepting specimens from physician-directed practices, and maintains the regulatory and proficiency-testing requirements necessary for Medicare and commercial insurance reimbursement. Revenues and professional headcount are not publicly disclosed. The firm operates from its sole Shoreline headquarters, though its specimen logistics network reaches all lower 48 states via overnight courier partnerships. Adjacent vehicles or external investment entities are not known. US BioTek's structural position is defined by its independent ownership in a consolidating sector. As a non-PE-backed, non-hospital-owned laboratory, it retains physician-directed clinical focus without the utilization pressure common in equity-backed lab companies — a posture that appeals to functional and integrative practitioners who prioritize clinical discretion in panel selection.
General information
Firm type
other
Year founded
2000
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Shoreline
Corporate office
Shoreline, WA, United States
Sector focus
Frequently asked questions
What testing categories does US BioTek specialize in?
US BioTek operates three core testing divisions: environmental and respiratory allergy profiles, food sensitivity panels (primarily IgG-mediated), and mycotoxin/toxicology assays. The lab uses ELISA immunology arrays for antibody detection, LC-MS/MS for quantitative toxicology, and PCR for molecular diagnostics. These panels are targeted toward functional and integrative medicine practitioners who use them as clinical decision-support tools.
Is US BioTek owned by a private equity firm or a hospital system?
No. US BioTek remains an independently held laboratory, per Washington State business records. This independent structure differentiates it from the majority of mid-sized reference labs, which have been acquired by private equity platforms or integrated into hospital-run laboratory outreach programs over the past decade.
Does US BioTek operate as a family office or an investment entity?
No. US BioTek is an operating clinical laboratory business, not a family office or investment vehicle. Its presence in an allocation database likely reflects a data categorization error. The firm generates revenue from patient testing services, not from managing assets or deploying capital into external investments.
Where does US BioTek accept specimens from?
US BioTek accepts physician-ordered specimens from all 50 United States. The lab's logistics network relies on overnight courier partnerships to transport ambient and frozen specimens from practitioner offices to its single processing facility in Shoreline, Washington.
How does US BioTek's food sensitivity testing differ from standard allergy testing?
Unlike standard IgE-mediated allergy testing, which detects immediate hypersensitivity, US BioTek's food sensitivity panels measure IgG antibody responses, per its published test methodology. These delayed-reaction panels are clinically utilized in functional medicine to guide elimination diets and dietary modification protocols, though their clinical utility remains a subject of debate in mainstream allergy and immunology societies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: